Table 4.
Lumiracoxib 100 mg o.d. (n = 755) | Lumiracoxib 100 mg b.i.d. (n = 1,519) | Celecoxib 200 mg o.d. (n = 758) | |
Patients with AEs, n (%) | 548 (72.6) | 1078 (71.0) | 526 (69.4) |
Patients with SAEs, n (%) | 41 (5.4) | 72 (4.7) | 48 (6.3) |
Fatal, n (%)† | 2 (0.3) | 7 (0.5) | 1 (0.1) |
Discontinuations due to AEs, n (%) | 98 (13.0) | 193 (12.7) | 87 (11.5) |
o.d. = once daily; b.i.d. = twice daily; AEs = adverse events; SAEs = serious adverse events; †all deaths occurring before database lock are included.